Palvella Therapeutics (NASDAQ:PVLA) Shares Gap Up – Time to Buy?

Palvella Therapeutics, Inc. (NASDAQ:PVLA)’s share price gapped up before the market opened on Tuesday . The stock had previously closed at $123.59, but opened at $129.31. Palvella Therapeutics shares last traded at $128.21, with a volume of 5,993 shares.

Analyst Ratings Changes

PVLA has been the topic of a number of analyst reports. HC Wainwright raised their target price on Palvella Therapeutics from $255.00 to $270.00 and gave the company a “buy” rating in a research report on Tuesday, March 24th. Stifel Nicolaus set a $250.00 target price on shares of Palvella Therapeutics in a research note on Tuesday, February 24th. Truist Financial set a $210.00 price target on Palvella Therapeutics in a research note on Tuesday, February 24th. Mizuho increased their price objective on shares of Palvella Therapeutics from $205.00 to $250.00 and gave the company an “outperform” rating in a report on Wednesday, February 25th. Finally, Chardan Capital lifted their price target on Palvella Therapeutics from $210.00 to $240.00 and gave the stock a “buy” rating in a report on Tuesday, March 31st. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $198.07.

Palvella Therapeutics Trading Up 1.6%

The stock has a market cap of $1.78 billion, a price-to-earnings ratio of -33.79 and a beta of -0.21. The company’s fifty day moving average is $123.76 and its two-hundred day moving average is $100.82.

Palvella Therapeutics (NASDAQ:PVLA) last announced its quarterly earnings data on Tuesday, March 31st. The company reported ($1.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.13). Analysts predict that Palvella Therapeutics, Inc. will post -4.87 EPS for the current year.

Insiders Place Their Bets

In other news, COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $117.99, for a total value of $507,592.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Elaine J. Heron bought 2,400 shares of the business’s stock in a transaction dated Friday, February 27th. The stock was acquired at an average cost of $125.00 per share, for a total transaction of $300,000.00. Following the completion of the acquisition, the director directly owned 47,812 shares in the company, valued at approximately $5,976,500. This trade represents a 5.28% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 20.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Palvella Therapeutics

A number of large investors have recently bought and sold shares of PVLA. Group One Trading LLC increased its stake in shares of Palvella Therapeutics by 151.5% during the fourth quarter. Group One Trading LLC now owns 332 shares of the company’s stock worth $35,000 after acquiring an additional 200 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in shares of Palvella Therapeutics by 11.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,090 shares of the company’s stock valued at $429,000 after buying an additional 433 shares during the period. Archer Investment Corp purchased a new stake in shares of Palvella Therapeutics in the third quarter valued at approximately $28,000. Bank of America Corp DE raised its position in Palvella Therapeutics by 12.3% in the third quarter. Bank of America Corp DE now owns 4,689 shares of the company’s stock worth $294,000 after acquiring an additional 515 shares in the last quarter. Finally, Deutsche Bank AG boosted its position in shares of Palvella Therapeutics by 8.7% during the 4th quarter. Deutsche Bank AG now owns 6,594 shares of the company’s stock worth $690,000 after purchasing an additional 528 shares in the last quarter. Hedge funds and other institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.